Building a total value chain through domestic biosimilar manufacturing and a CDMO joint venture

「In November 2025, the Company resolved at a Board of Directors meeting to enter into an agreement with Kidswell Bio Corporation (head office: Chuo-ku, Tokyo), Chiome Bioscience Inc. (head office: Shibuya-ku, Tokyo), and Mycenax Biotech Inc. (head office: Hsinchu County, Taiwan), under which the 4 companies will establish a joint venture to manufacture active pharmaceutical ingredients and drug products for biosimilars. Through this agreement, the Company will develop domestic manufacturing facilities for biopharmaceuticals, including biosimilars, advance a CDMO business for biosimilars and other products through the joint venture by leveraging the strengths of the 4 companies, and combine these capabilities with the Group's distribution functions to build a total value chain for biosimilars and other products. The Company will also work to raise Japan's domestic self-sufficiency rate for biosimilars, establish a stable supply system, export the manufactured biosimilar active pharmaceutical ingredients and drug products, and develop human resources involved in biopharmaceutical development and manufacturing in Japan, thereby contributing to the development of the biopharmaceutical industry.」